FHI Form 144 filed for $178K insider stock sale on NYSE
Rhea-AI Filing Summary
Federated Hermes, Inc. (FHI) filed a Form 144 notice for a planned sale of restricted common stock. The filing covers the proposed sale of 3,721 common shares through Morgan Stanley Smith Barney LLC on the NYSE, with an indicated aggregate market value of $178,023.43. These shares were acquired on 11/19/2025 through restricted stock vesting under a registered plan, with the purchase price effectively paid through services rendered. The filing states that the seller represents they are not aware of any undisclosed material adverse information about the issuer’s operations.
Positive
- None.
Negative
- None.
FAQ
What does the Form 144 filing for FHI disclose?
The Form 144 for Federated Hermes, Inc. (FHI) discloses a planned sale of 3,721 shares of common stock by an affiliated seller under Rule 144.
How many Federated Hermes (FHI) shares are planned to be sold and at what value?
The notice covers 3,721 common shares of FHI with an indicated aggregate market value of $178,023.43 at the time of the filing.
How were the FHI shares in this Form 144 acquired?
The 3,721 FHI common shares were acquired on 11/19/2025 as restricted stock vesting under a registered plan, with consideration described as services rendered.
Which broker will handle the Form 144 sale for Federated Hermes (FHI)?
The planned sale of FHI common stock will be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, based at 1 New York Plaza, New York, NY 10004.
On which exchange will the FHI shares in this Form 144 be sold and when?
The filing lists the NYSE as the securities exchange and shows an approximate date of sale of 11/19/2025 for the 3,721 common shares.
How many Federated Hermes (FHI) shares are outstanding according to this Form 144?
The Form 144 states that 77,537,867 shares of FHI common stock were outstanding at the time of the notice.
What representation does the seller make in the FHI Form 144?
The seller represents that they do not know any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed.